Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A general and biomedical perspective of viral quasispecies, Viral quasispecies

  • Domingo, Esteban
  • Martínez-González, Brenda
  • Somovilla, Pilar
  • García-Crespo, Carlos
  • Soria, María Eugenia
  • de Ávila, Ana Isabel
  • Gadea, Ignacio
  • Perales, Celia
Viral quasispecies refers to the complex and dynamic mutant distributions (also termed mutant spectra, clouds or swarms) that arise as a result of high error rates during RNA genome replication. The mutant spectrum of individual RNA virus populations is modified by continuous generation of variant genomes, competition and interactions among them, environmental influences, bottleneck events, and bloc transmission of viral particles. Quasispecies dynamics provides a new perspective on how viruses adapt, evolve and cause disease, and sheds light on strategies to combat them. Molecular flexibility, together with ample opportunity of mutant cloud traffic in our global world, are key ingredients of viral disease emergences, as exemplified by the recent COVID-19 pandemic. In the present article we present a brief overview of the molecular basis of mutant swarm formation and dynamics, and how the latter relates to viral disease and epidemic spread. We outline future challenges derived of the highly diverse cellular world in which viruses are necessarily installed., The work was supported by the Ministerio de Ciencia e Innovación, grants PID2020-113888RB-I00/AEI/10.13039/501100011033 and 202220I116, by the Ministerio de Ciencia, Innovación y Universidades (MICIU), grant PID2023-146622OB I00 financed by MICIU/AEI/10.13039/501100011033 and by FEDER, UE, through the “Severo Ochoa” Programmes for Centres of Excellence in R&D [CEX2021-001154-S and CEX2023-001386-S]. The work was also supported by the European Commission- Next Generation EU (regulation EU 2020/2024) through the CSIC’s Global Health Platform (PTI Salud Global). The work was also funded by grants PI21/00139 funding from Instituto de Salud Carlos III (ISCIII), co-funded by the European Union, CSIC COV19-014 from Agencia Estatal Consejo Superior de Investigaciones Científicas (CSIC) and project 525/C/2021 from Fundació La Marató de TV3, grants 202136-30 and 202136-31. We also acknowledge the project S2018/BAA-4370 (PLATESA2 from Comunidad de Madrid/FEDER). Institutional grants from the Fundación Ramón Areces and Banco Santander to the CBMSO are also acknowledged. The team at CBMSO belongs to the Global Virus Network (GVN), and to the Biomedicine Unit of Universidad de Castilla La Mancha (UCLM), associated with CSIC. B.M.-G. is supported by predoctoral contract PFIS FI19/00119 from Instituto de Salud Carlos III cofinanced by Fondo Social Europeo (FSE), “El FSE invierte en tu futuro”. P.S. is supported by postdoctoral contract Margarita Salas, CA1/RSUE/2021 from MCIU. C.G.-C. was supported by predoctoral contract PRE2018-083422 from MCIU, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 biological clones are genetically heterogeneous and include clade-discordant residues

  • Ávila, Ana Isabel de
  • Soria, María Eugenia
  • Martínez-González, Brenda
  • Somovilla, Pilar
  • Mínguez, Pablo
  • Salar-Vidal, Llanos
  • Esteban-Muñoz, Mario
  • Martín-García, Marta
  • Zuñiga, Sonia
  • Solá Gurpegui, Isabel
  • Enjuanes Sánchez, Luis
  • Gadea, Ignacio
  • Perales, Celia
  • Domingo, Esteban
Defective genomes are part of SARS-CoV-2 quasispecies. High-resolution, ultra-deep sequencing of bulk RNA from viral populations does not distinguish RNA mutations, insertions, and deletions in viable genomes from those in defective genomes. To quantify SARS-CoV-2 infectious variant progeny, virus from four individual plaques (biological clones) of a preparation of isolate USA-WA1/2020, formed on Vero E6 cell monolayers, was subjected to further biological cloning to yield 9 second-generation and 15 third-generation sub-clones. Consensus genomic sequences of the biological clones and sub-clones included an average of 2.8 variations per viable genome, relative to the consensus sequence of the parental USA-WA1/2020 virus. This value is 6.5-fold lower than the estimates for biological clones of other RNA viruses such as bacteriophage Qβ, foot-and-mouth disease virus, or hepatitis C virus in cell culture. The mutant spectrum complexity of the nsp12 (polymerase)- and spike (S)-coding region was unique in the progeny of each of 10 third-generation sub-clones; they shared 2.4% of the total of 164 different mutations and deletions scored in the 3,719 genomic residues that were screened. The presence of minority out-of-frame deletions revealed the ease of defective genome production from an individual infectious genome. Several low-frequency point mutations and deletions were clade-discordant in that they were not typical of USA-WA1/2020 but served to define the consensus sequences of future SARS-CoV-2 clades. Implications for SARS-CoV-2 adaptability and COVID-19 control of the viable genome heterogeneity and the generation of complex mutant spectra from individual genomes are discussed.IMPORTANCESequencing of biological clones is a means to identify mutations, insertions, and deletions located in viable genomes. This distinction is particularly important for viral populations, such as those of SARS-CoV-2, that contain large proportions of defective genomes. By sequencing biological clones and sub-clones, we quantified the heterogeneity of the viable complement of USA-WA1/2020 to be lower than exhibited by other RNA viruses. This difference may be due to a reduced mutation rate or to limited tolerance of the large coronavirus genome to incorporate mutations and deletions and remain functional or a combination of both influences. The presence of clade-discordant residues in the progeny of individual biological sub-clones suggests limitations in the occupation of sequence space by SARS-CoV-2. However, the complex and unique mutant spectra that are rapidly generated from individual genomes suggest an aptness to confront selective constraints., The work was supported by the Ministerio de Ciencia e Innovación, grants PID2020-113888RB-I00/AEI/10.13039/501100011033 and 202220I116, by the Ministerio de Ciencia, Innovación y Universidades (MICIU), grant PID2023-146622OB-I00 financed by MICIU/AEI/10.13039/501100011033 and by FEDER, UE, through the “Severo Ochoa” Programmes for Centers of Excellence in R&D (CEX2021-001154-S and CEX2023-001386-S). The work was also supported by the European Commission Next-Generation EU (regulation EU 2020/2024) through the CSIC’s Global Health Platform (PTI Salud Global). The work was also funded by grants PI21/00139 funding from Instituto de Salud Carlos III (ISCIII), co-funded by the European Union, CSIC-COV19-014 from Agencia Estatal Consejo Superior de Investigaciones Científicas (CSIC) and project 525/C/2021 from Fundació La Marató de TV3, grants 202136-30 and 202136-31. We also acknowledge the projects TEC-607 2024/BIO-66 (SALAINDEC-CM from Comunidad de Madrid/FEDER) and S2018/BAA-4370 (PLATESA2 from Comunidad de Madrid/FEDER). Institutional grants from the Fundación Ramón Areces and Banco Santander to the CBMSO are also acknowledged. The team at CBM belongs to the Global Virus Network (GVN) and to the Biomedicine Unit of Universidad de Castilla La Mancha (UCLM), associated with CSIC. B.M.-G. is supported by predoctoral contract PFIS FI19/00119 from Instituto de Salud Carlos III cofinanced by Fondo Social Europeo (FSE), “El FSE invierte en tu futuro.” P.S. is supported by postdoctoral contract Margarita Salas, CA1/RSUE/2021 from MCIU. P.M. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CPII21/00015), cofinanced by the European Regional Development Fund (ERDF)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 mutant spectrum complexity is an epidemiologically evolvable trait

  • Martínez-González, Brenda
  • Soria, María Eugenia
  • Ávila, Ana Isabel de
  • Somovilla, Pilar
  • Aguilar-Sabido, Claudia
  • Mínguez, Pablo
  • Ferrer-Orta, Cristina
  • Salar-Vidal, Llanos
  • Lorenzo-Redondo, Ramón
  • Delgado, Soledad
  • Morán, Federico
  • Verdaguer, Núria
  • Gadea, Ignacio
  • Domingo, Esteban
  • Perales, Celia
RNA virus populations consist of complex and dynamic mutant spectra in which most individual genomes differ in one or more positions from the other genomes of the same population. This behavior, known as quasispecies dynamics, applies to SARS-CoV-2 which exhibits intrahost genetic and functional heterogeneity while evolving at a high rate in the human population. In the present study, we describe a remarkable reduction in mutant spectrum complexity (intrahost viral genome heterogeneity) in SARS-CoV-2 isolates of late relative to early COVID-19 waves, as they reached Madrid (Spain) from 2020 until 2022. In contrast, the consensus (average) sequence of the corresponding isolates displayed a continuing divergence from the initial Wuhan-Hu-1 virus as the pandemic advanced. The mutant spectrum complexity developed upon replication in Vero E6 cells of the isolates from the first and sixth COVID-19 waves, as well as of biological clones retrieved from them, was similar. Therefore, the mutant spectrum complexity reduction observed in vivo was not due to an increased accuracy of the viral replicative machinery, but rather to other factors related to viral epidemiology or pathogenesis. Such possible factors and their implications for viral trait modifications in the course of a viral pandemic are discussed. The results establish that mutant spectrum complexity of genetically variable viruses can be an epidemiologically evolvable trait., This work was supported by the Spanish Ministry of Science and Innovation, grants PID2020-117976GB-I00, PID2020-113888RB-I00/AEI/10.13039/501100011033 and 202220I116, by the Ministerio de Ciencia, Innovación y Universidades (MICIU), grant PID2023-146622OB-I00 financed by MICIU/AEI/10.13039/501100011033, by Fondo Europeo de Desarrollo Regional (FEDER), UE, through the “Severo Ochoa” Program for Centres of Excellence in Research and Development (CEX2021-001154-S), and by the European Commission-Next Generation EU (regulation EU 2020/2024) through the Consejo Superior de Investigaciones Científicas (CSIC’s) Global Health Platform [Plataforma Temática Interdisciplinar (PTI) Salud Global]. The work was also funded by grants PI21/00139 from Instituto de Salud Carlos III, CSIC-COV19-014 from CSIC and project 525/C/2021 from Fundació La Marató de TV3, grants 202136-30 and 202136-31. We also acknowledge the projects TEC-2024/BIO-66 (SALAINDEC-CM from Comunidad de Madrid/FEDER) and S2018/BAA-4370 (PLATESA2 from Comunidad de Madrid/FEDER). Institutional grants from the Fundación Ramón Areces and Banco Santander to the CBM are also acknowledged. The team at Centro de Biología Molecular (CBM) belongs to the Global Virus Network, and to the Biomedicine Unit of Universidad de Castilla La Mancha, associated with CSIC. B.M.-G. is supported by predoctoral contract PFIS FI19/00119 from Instituto de Salud Carlos III cofinanced by Fondo Social Europeo (FSE), “El FSE invierte en tu futuro.” P.S. is supported by postdoctoral contract Margarita Salas, CA1/RSUE/2021 from Ministerio de Ciencia, Innovación y Universidades (MICIU). P.M. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CPII21/00015), cofinanced by the European Regional Development Fund., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001154-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Synergistic antiviral effects of structure-guided peptides and a mutagenic base analog on SARS-CoV-2 replication

  • Ortega Del Campo, Sergio
  • Fernández Ballester, Gregorio Joaquín
  • Blanes Mira, Clara
  • Guirado Osorio, Víctor
  • Díaz Martínez, Luis
  • de Ávila, Ana Isabel
  • Soria, María Eugenia
  • Martínez-González, Brenda
  • Villena González, Francisco José
  • Gómez-Maldonado, Josefa
  • Viciana Ramos, María Isabel
  • Clavijo Frutos, Encarnación
  • Santos González, Jesús L
  • Bastolla, Ugo
  • Perales, Celia
  • Domingo, Esteban
  • Viguera, Enrique
  • Fernández Escamilla, Ana María
  • Grande-Pérez, Ana
The limited durability of vaccine protection and the rapid emergence of SARS-CoV-2 variants highlight the need for antiviral strategies that extend beyond vaccination and conventional small-molecule inhibitors. Here, we explored a dual approach combining structure-guided peptides predicted to interfere with the viral replication complex with lethal mutagenesis to limit SARS-CoV-2 replication. Using the crystallographic interfaces of nsp10 with nsp14 and nsp16, we designed short inhibitory peptides predicted to interact with the viral proofreading and RNA-capping machinery. In parallel, the mutagenic analog 5-fluorouracil was evaluated to determine its effect on SARS-CoV-2 in Vero E6 cells. Peptides P1 and P6 exhibited potent antiviral activity with minimal cytotoxicity, whereas 5-FU reduced specific infectivity without impairing genome replication. Combined treatment with 5-FU and peptide P1 resulted in >104-fold reduction in infectious virus, achieving near-complete loss of infectivity at non-cytotoxic concentrations. Next-generation sequencing revealed that dual treatment increased mutation frequency, altered mutant spectra, and decreased genome stability, consistent with progression toward error catastrophe. Principal component analysis confirmed that combined treatment generated mutant spectra distinct from either monotherapy. These findings are consistent with a dual antiviral strategy in which structure-guided peptides designed to interact with components of the SARS-CoV-2 replication complex act in combination with lethal mutagenesis to produce a synergistic interaction between these two complementary processes. This integrated approach suggests a potential broad-spectrum antiviral strategy with applicability to other coronaviruses., This work was funded by grant CV20-10932 (PI: AG-P) from the Junta de Andalucía, co-financed with FEDER funds, and partially funded by Fundación Bancaria Unicaja. Partial funding for open access charges was provided by the Universidad de Málaga. U.B. was supported by grant PID2023-151032NB-C2 from the Spanish Ministry of Science (MCIU), the Spanish Research Agency (AEI/10.13039/501100011033/), and FEDER, EU. Research at the CBMSO is facilitated by the Fundación Ramón Areces and supported by the Ministerio de Ciencia, Innovación y Universidades (MICIU), through grant PID2023-146622OB-I00, financed by MICIU/AEI/10.13039/501100011033 and FEDER, EU, and by the “Severo Ochoa” Program for Centres of Excellence in Research and Development (CEX2021- 001154-S). We also acknowledge project TEC-607 2024/BIO-66 (SALAINDEC-CM from Comunidad de Madrid/FEDER). S.O.D.C. acknowledges financial support from Fundación Martín Varona. A.M.F.E. acknowledges a Teaching Staff Retraining Grant (2023), Spanish Ministry of Universities, and CIBEST/2024/114 from Generalitat Valenciana. We thank Dr. Luis Enjuanes (CNB-CSIC, Spain) for providing Vero E6 cells and Dr. Francisco Sobrino (CBMSO) for providing the VFA control peptide, Peer reviewed